Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
Korean Journal of Transplantation · 2020
DOI: 10.4285/atw2020.op-1033 ↗At a glance
Journal article in Korean Journal of Transplantation, 2020. Written by Incheon Kang and 1 co-authors.
Abstract (original language)
The objective of this study was to investigate whether everolimus (EVR) use affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). Methods: Data from 303 consecutive patients with HCC who underwent LT were retrospectively reviewed. The patients were divided into two groups: (1) patients treated with EVR in combination with calcineurin inhibitors (CNI) (EVR group, n=114), and (2) patients treated with CNI-based therapy without EVR (non-EVR group, n=189). Disease-free survival (DFS) and overall survival (OS) were compared between two groups, and prognostic factors for DFS and OS were evaluated.
Cite
APA
Kang, I., & Joo, D. J. (2020). Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma. Korean Journal of Transplantation. https://doi.org/10.4285/atw2020.op-1033
Vancouver
Kang I, Joo DJ. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma. Korean Journal of Transplantation. 2020. doi:10.4285/atw2020.op-1033
BibTeX
@article{Kang2020,
author = {Kang, Incheon and Joo, Dong Jin},
title = {Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma},
journal = {Korean Journal of Transplantation},
year = {2020},
doi = {10.4285/atw2020.op-1033}
}
EUVIMED